Skip to main content
Clinical Trials/NCT01067599
NCT01067599
Completed
Not Applicable

Novel Determinants and Measures of Smokeless Tobacco Use: Study 2 Effects of Switching Levels of Nicotine and TSNA in Products on Smokeless Tobacco Use

University of Minnesota2 sites in 1 country278 target enrollmentMarch 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tobacco Use Disorder
Sponsor
University of Minnesota
Enrollment
278
Locations
2
Primary Endpoint
1. To determine if switching to ST products with reduced toxicant levels will result in reduction of biomarkers of exposure and toxicity. 2. To determine the nicotine levels of ST that would lead to the greatest reduction in tobacco toxicant exposure.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The research project will determine the level of nicotine in ST products that will lead to the greatest reduction in toxicant exposure

Detailed Description

This is a randomized, multi-site trial determining the effects of switching smokeless tobacco (ST) users to lower toxicant ST products which vary in nicotine levels on biomarkers of exposure and patterns of use. ST users will undergo a two week baseline assessment period and then randomly assigned to one of three oral tobacco products (lower NNK plus NNN product with three different levels of nicotine) for a period of 8-weeks. Follow-up will occur at 9 and 20 weeks.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
October 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Using a consistent and daily amount of ST with specific nicotine and tobacco-specific nitrosamine (TSNA) levels for the past year;
  • In good physical health (no unstable medical condition);
  • Stable, good mental health (e.g., no recent unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the DSM-IV criteria).

Exclusion Criteria

  • Subjects must not be currently using other tobacco or nicotine products.
  • Female subjects cannot be pregnant or nursing.

Outcomes

Primary Outcomes

1. To determine if switching to ST products with reduced toxicant levels will result in reduction of biomarkers of exposure and toxicity. 2. To determine the nicotine levels of ST that would lead to the greatest reduction in tobacco toxicant exposure.

Time Frame: 8 weeks

Secondary Outcomes

  • To determine the extent to which varying low nicotine ST products leads to compensatory tobacco use.(8 weeks)

Study Sites (2)

Loading locations...

Similar Trials